Use of ABO-incompatible renal transplants from living donors has proven a viable and practical transplantation strategy. The protocols devised through the Johns Hopkins Incompatible Kidney Transplant Program could result in the most rapid escalation of access to organs in the modern era of transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Montgomery, R. A. et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 87, 1246–1255 (2009).
Liem, Y. S. & Weimar, W. Early living-donor kidney transplantation: a review of the associated survival benefit. Transplantation 87, 317–318 (2009).
US Department of Health & Human Services OPTN: Organ Procurement Transplantation Network [online], (2009).
Alexandre, G. P. et al. Present experience in a series of 26 ABO-incompatible living donor renal allografts. Transplant. Proc. 19, 4538–4342 (1987).
Tanabe, K. et al. Long-term results of ABO-incompatible living kidney transplantation: a single center experience. Transplantation 65, 224–228 (1998).
Toki, D. et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am. J. Transplant. 9, 567–577 (2009).
Genberg, H., Kumlien, G., Wennberg, L., Berg, U. & Tydén, G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85, 1745–1754 (2008).
Allen, G. et al. Rapid accommodation of an A1 renal allograft after preconditioning for ABO-incompatible transplantation. Contrib. Nephrol. 162, 35–46 (2009).
Rees, M. A. et al. A nonsimultaneous, extended, altruistic-donor chain. N. Engl. J. Med. 360, 1096–1101 (2009).
Stgall, M. et al. Prevention of acute humoral rejection with C5 inhibition [abstract 178]. Am. J. Transplant. 9 (Suppl. 2), 241 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares associations with Bristol–Myers Squibb and Talecris Biotherapeutics as consultant and recipient of grant/research support and Pfizer as recipient of grant/research support. The author also holds US Patent 6,171,585 B1.
Rights and permissions
About this article
Cite this article
Jordan, S. ABO-incompatible renal transplants: time for increased use?. Nat Rev Nephrol 5, 491–492 (2009). https://doi.org/10.1038/nrneph.2009.131
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.131
